0001144204-15-066811.txt : 20151118 0001144204-15-066811.hdr.sgml : 20151118 20151118193240 ACCESSION NUMBER: 0001144204-15-066811 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151116 FILED AS OF DATE: 20151118 DATE AS OF CHANGE: 20151118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KALOBIOS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001293310 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770557236 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 442 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.243.3100 MAIL ADDRESS: STREET 1: 442 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moradi David CENTRAL INDEX KEY: 0001658843 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35798 FILM NUMBER: 151241980 MAIL ADDRESS: STREET 1: 379 WEST BROADWAY CITY: NEW YORK STATE: NY ZIP: 10021 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Anthion Partners II LLC CENTRAL INDEX KEY: 0001658549 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35798 FILM NUMBER: 151241981 BUSINESS ADDRESS: STREET 1: 379 WEST BROADWAY CITY: NEW YORK STATE: NY ZIP: 10012 BUSINESS PHONE: 212-404-6677 MAIL ADDRESS: STREET 1: 379 WEST BROADWAY CITY: NEW YORK STATE: NY ZIP: 10012 4/A 1 v425171_4a.xml OWNERSHIP DOCUMENT X0306 4/A 2015-11-16 2015-11-18 0 0001293310 KALOBIOS PHARMACEUTICALS INC KBIO 0001658549 Anthion Partners II LLC 379 WEST BROADWAY NEW YORK NY 10012 0 0 1 0 0001658843 Moradi David 379 WEST BROADWAY NEW YORK NY 10012 0 0 0 1 Managing Member Common Stock 2015-11-16 4 P 0 225963 1.26 A 293900 D Common Stock 2015-11-16 4 P 0 225963 1.26 A 293900 I Through Anthion Partners II LLC Common Stock 2015-11-16 4 P 0 17100 1.76 A 311000 D Common Stock 2015-11-16 4 P 0 17100 1.76 A 311000 I Through Anthion Partners II LLC Common Stock 2015-11-17 4 P 0 113800 1.69 A 424800 D Common Stock 2015-11-17 4 P 0 113800 1.69 A 424800 I Through Anthion Partners II LLC The prices reported in Column 4 are weighted average prices. Anthion Partners II LLC, on behalf of David Moradi, the Managing Member of Anthion Partners II LLC, purchased 225,963 shares in multiple transactions at prices ranging from $0.7 to $1.69, inclusive. The reporting persons undertake to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. The securities reported herein are owned directly by Anthion Partners II LLC and indirectly by David Moradi, the Managing Member of Anthion Partners II LLC. Both Anthion Partners II LLC and David Moradi are members of a "group" (with other persons) for purposes of Section 13(d) of the Securities Exchange Act of 1934. There is no voting or ownership agreement amongst the group members and the other members of the group do not have a pecuniary interest in the shares reported herein. Correspondingly, neither Anthion nor Mr. Moradi have a pecuniary interest in the shares owned by the other members of the group. The prices reported in Column 4 are weighted average prices. Anthion Partners II LLC, on behalf of David Moradi, the Managing Member of Anthion Partners II LLC, purchased 17,100 shares in multiple transactions at prices ranging from $1.7 to $1.85, inclusive. The reporting persons undertake to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. The prices reported in Column 4 are weighted average prices. Anthion Partners II LLC, on behalf of David Moradi, the Managing Member of Anthion Partners II LLC, purchased 113,800 shares in multiple transactions at prices ranging from $1.42 to $1.96, inclusive. The reporting persons undertake to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4. This Form 4 is being amended to reflect David Moradi's beneficial ownership. /s/ David Moradi, Managing Member of Anthion Partners II LLC 2015-11-18 /s/ David Moradi 2015-11-18